Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.52 |
|---|---|
| 52-week range | $1.18 - $3.64 |
| 50-day moving average | $1.39 |
| 200-day moving average | $1.72 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.64 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.515 from 2023-02-06
| 1 week (2023-02-01) | 3.06% |
|---|---|
| 1 month (2023-01-06) | 7.45% |
| 3 months (2022-11-08) | 17.44% |
| 6 months (2022-08-08) | -34.98% |
| 1 year (2022-02-04) | -55.83% |
|---|---|
| 2 years (2021-02-08) | -95.35% |
| 3 years (2020-02-04) | N/A |
| 5 years (2018-02-04) | N/A |
| Revenue TTM | $4.8 million |
|---|---|
| Gross profit TTM | $-74,395,000 |
| Return on assets TTM | -20.8% |
| Return on equity TTM | -41.12% |
| Profit margin | 0% |
| Book value | $5.00 |
| Market capitalisation | $55.4 million |
TTM: trailing 12 months
We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.
Bolt Biotherapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.